주요 내용으로 건너 뛰기

Dose Guidance for a Novel Combination Therapy to Treat Head and Neck Squamous Cell Carcinoma (HNSCC) for Patients with HRAS/PIK3CA Variants Using a Quantitative Systems Pharmacology (QSP) Model​

In this poster, we present a human QSP model that predicts the tumor response of tipifarnib/alpelisib combination therapy for five distinct genotypes of Head and Neck Squamous Cell Carcinoma (HNSCC) patients: PIK3CA mut, PIK3CA amp, HRAS OE positive, PIK3CA mut/HRAS OE positive, PIK3CA amp/HRAS OE positive​.

Powered by Translations.com GlobalLink Web Software